In a collaborative effort between the Department of Atomic Energy and IDRS Labs in Bengaluru, scientists have achieved a major breakthrough in cancer care with the development of AKTOCYTE tablets. Aimed at improving the quality of life for cancer patients undergoing radiotherapy, the tablets have shown remarkable results, particularly in addressing radiotherapy-induced Cystitis, a condition causing blood in urine, in pelvic cancer patients.

The project, which involved experts from institutions such as Bhabha Atomic Research Centre in Mumbai, Tata Memorial Hospital in Mumbai, and the Advanced Centre for Training Research and Education in Cancer in Navi Mumbai, focused on minimizing the side effects of radiotherapy. Notably, patients treated with AKTOCYTE tablets demonstrated extraordinary recovery, eliminating the necessity for surgical removal of the urinary bladder.

AKTOCYTE tablets serve as a multifaceted approach to cancer care, designed as an adjuvant to cancer radiotherapy, a regenerative nutraceutical, an immunomodulator, and an antioxidant. The tablets' approval by the Food Safety and Standards Authority of India (FSSAI) underscores their safety and compliance, offering assurance to healthcare professionals and patients alike regarding efficacy and quality.

Positioned as more than a supplement, AKTOCYTE tablets are anticipated to enter the market in January 2024, revolutionizing cancer treatment protocols. This collaboration between the Department of Atomic Energy and the industry represents a pivotal moment in the convergence of scientific innovation and practical solutions for cancer care, marking a significant step forward in the quest for more effective cancer management.